![Robert Selliah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Selliah
Keine laufenden Positionen mehr
Profil
Robert Selliah worked as a Principal at ArQule, Ribapharm, Alcon Laboratories, Prolexys Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals.
He also served as Vice President-Integrated Discovery Services at SAI Life Sciences Ltd.
from 2010 to 2014.
He holds a doctorate degree from The University of Texas at Austin.
Ehemalige bekannte Positionen von Robert Selliah
Unternehmen | Position | Ende |
---|---|---|
Ribapharm, Inc.
![]() Ribapharm, Inc. Pharmaceuticals: MajorHealth Technology Ribapharm, Inc. discovers, develops and markets antiviral and anticancer pharmaceuticals. The company is located in Costa Mesa, CA | Corporate Officer/Principal | - |
ARQULE, INC. | Corporate Officer/Principal | - |
Boehringer Ingelheim Pharmaceuticals, Inc.
![]() Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | - |
Alcon Laboratories, Inc.
![]() Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX. | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - |
Ausbildung von Robert Selliah
The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
SAI Life Sciences Ltd.
![]() SAI Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology SAI Life Sciences Ltd. manufactures, develops, and discovers pharmaceutical drugs. The company was founded in 1999 and is headquartered in Hyderabad, India. | Health Technology |
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Alcon Laboratories, Inc.
![]() Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
![]() Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
ArQule, Inc.
![]() ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Ribapharm, Inc.
![]() Ribapharm, Inc. Pharmaceuticals: MajorHealth Technology Ribapharm, Inc. discovers, develops and markets antiviral and anticancer pharmaceuticals. The company is located in Costa Mesa, CA | Health Technology |